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Abstract
Background: Tuberculosis (TB) continues to be an important cause of fatal and non-fatal burden in Brazil. In this
study, we present estimates for TB burden in Brazil from 1990 to 2017 using data from the Global Burden of
Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017).
Methods: This descriptive study used GBD 2017 findings to report years of life lost (YLLs), years lived with disability
(YLDs), and disability-adjusted life years (DALYs) of TB in Brazil by sex, age group, HIV status, and Brazilian states,
from 1990 to 2017. We also present the TB burden attributable to independent risk factors such as smoking, alcohol
use, and diabetes. Results are reported in absolute number and age-standardized rates (per 100,000 inhabitants)
with 95% uncertainty intervals (UIs).
Results: In 2017, the number of DALYs due to TB (HIV-negative and HIV-positive combined) in Brazil was 284,323
(95% UI: 240,269–349,265). Among HIV-negative individuals, the number of DALYs was 196,366 (95% UI: 189,645–
202,394), while 87,957 DALYs (95% UI: 50,624–146,870) were estimated among HIV-positive individuals. Between
1990 and 2017, the absolute number and age-standardized rates of DALYs due to TB at the national level
decreased by 47.0% and 68.5%, respectively. In 2017, the sex–age-specific TB burden was highest among males and
in children under-1 year and the age groups 45–59 years. The Brazilian states with the highest age-standardized
DALY rates in 2017 were Rio de Janeiro, Pernambuco, and Amazonas. Age-standardized DALY rates decreased for
all 27 Brazilian states between 1990 and 2017. Alcohol use accounted for 47.5% of national DALYs due to TB
among HIV-negative individuals in 2017, smoking for 17.9%, and diabetes for 7.7%.
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Conclusions: GBD 2017 results show that, despite the remarkable progress in reducing the DALY rates during the
period, TB remains as an important and preventable cause of health lost to due premature death and disability in
Brazil. The findings reinforce the importance of strengthening TB control strategies in Brazil through integrated and
multisectoral actions that enable the access to prevention, early diagnosis, and timely treatment, with emphasis on
high-risk groups and populations most vulnerable to the disease in the country.
Keywords: Tuberculosis, Burden of disease, Disability-adjusted life year, Brazil
Background
Tuberculosis (TB) is an infectious disease that usually af-
fects the lungs (pulmonary TB), but can also affect other
parts of the body (extrapulmonary TB) [1]. Presently,
about one-quarter of the world’s population is infected
with Mycobacterium tuberculosis, but a relatively small
proportion (5–15%) will develop TB disease during their
lifetime [2].
TB remains a public health problem worldwide, particu-
larly in low- and middle-income countries, despite all ef-
forts to control the disease and recent achievements in
reducing incidence and mortality rates [1, 3]. In 2018,
there were an estimated 10 million active TB cases [1] and
about 45 million disability-adjusted life years (DALYs)
worldwide in 2017 [4]. TB is one of the leading causes of
death worldwide, with an estimate of 1.5 million TB
deaths in 2018 (including 0.25 million people with HIV)
[1]. An estimated 1.1 million children (0–14 years of age)
fell ill with TB and 205,000 children died from the disease
in 2018 [1]. More than 95% of TB deaths occurred in low-
and middle-income countries [1].
Like other countries, Brazil has shown a decline in in-
cidence and mortality rates over recent decades, mainly
associated with the improvement of population living
conditions and the performance of TB control pro-
grammes [5, 6]. However, the disease burden continues
to be significant in the country [1, 6]. Brazil is one of the
30 high TB burden countries regarding of estimated ab-
solute number of incident TB cases and incident TB
cases among people living with HIV [1]. In 2018, about
76,000 new TB cases (including 6700 HIV-positive cases
and about 1000 drug-resistant TB cases) and 4500 TB
deaths were reported in Brazil, resulting in an incidence
rate of 36.6 cases/100,000 inhabitants and a mortality
rate of 2.2 deaths/100,000 inhabitants [6]. The geograph-
ical distribution of TB is markedly by regional heteroge-
neities in the country, with incidence TB rates ranging
from 22.8 cases/100,000 inhabitants in the Central-West
region to 47.7 cases/100,000 inhabitants in the North re-
gion in 2018 [5, 6].
Despite the social and health impact of TB in Brazil, few
systematic and large-scale studies have been done to as-
sess the fatal and non-fatal burden of TB in the country
[7, 8]. The comprehensive assessment and understanding
of the trends and levels in TB burden is crucial to track
the success of control programmes and to identify
remaining intervention challenges seeking to achieve the
specific targets of the sustainable development goals
(SDGs) until 2030 [3, 9, 10] and World Health
Organization (WHO)’s End TB Strategy to end the TB
epidemic by 2035 [11]. In this paper, we used results from
the Global Burden of Diseases, Injuries, and Risk Factors
Study 2017 (GBD 2017) to assess the levels and trends in
the burden of TB in Brazil by sex, age group, HIV status,
and Brazilian states, from 1990 to 2017. We also report
the TB burden attributed to the independent effects of risk
factors among HIV-negative individuals, including smok-
ing, alcohol use, and diabetes.
Methods
GBD overview
This study has been conducted as part of the GBD study,
coordinated by the Institute for Health Metrics and Evalu-
ation (IHME; http://www.healthdata.org) at the University
of Washington, USA. The GBD study is a systematic and
scientific effort to quantify the comparative magnitude of
health loss due to diseases, injuries, and risk factors by
sex, age group, and location over time [4]. The GBD study
uses as the main population health metric the disability-
adjusted life years (DALYs), a summary measure of health
loss due to both fatal and non-fatal disease burden [4].
DALYs are estimated by summing up the years lived with
any short term or long-term disability (YLDs) and years of
life lost (YLLs) due to premature mortality for a given
cause [4, 12, 13]. One DALY is equivalent to one healthy
year of life lost due to a specific disease or injury [4].
GBD 2017 provides consistent estimates of health lost
for 359 diseases and injuries and 84 risk factors for 195
countries and territories, some of which were estimated
at the subnational level, including Brazil [4, 14]. For each
cycle of the GBD study, the entire time series is re-
estimated to incorporate new data and methods. Thus,
the GBD 2017 results supersede all previous GBD results
[15]. A detailed description of general methodological
approaches of GBD 2017 and the specific methodology
used to estimate TB burden has been described else-
where [12–14, 16]. In this study, we used data and esti-
mates from the GBD 2017 study to explore the TB
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burden by HIV status (HIV-positive individuals, HIV-
negative individuals, and HIV-negative and HIV-positive
combined) in Brazil from 1990 to 2017.
Case definition of tuberculosis
The case definition of TB includes all forms, including
pulmonary and extrapulmonary TB, which are bacterio-
logically confirmed or clinically diagnosed [3, 10]. The
GBD category of TB is defined and identified according
to the International Classification of Diseases (ICD)-9
codes 010–19.9, 137–137.9, 138.0–138.9, 320.4, and
730.4–730.6, and the ICD-10 codes A10–19.9, B90–90.9,
K67.3, K93.0, M49.0, and P37.0 [3, 12, 13]. For TB-HIV,
the ICD-10 code is B20.0 [3, 10].
Geographical location and time period
Brazil, officially called the Federative Republic of Brazil,
is the South America’s largest country (total territory of
8.5 million km2) and has an estimated population of
210.1 million inhabitants in 2019 [17]. The country is di-
vided politically and administratively into 27 federative
units (26 states and the Federal District) and 5570 muni-
cipalities, grouped into five geographic macro-regions
(South, Southeast, Central-West, North, and Northeast).
In this study, we present results for TB burden at the na-
tional level (entire country) and for all federative units,
herein simply named as states.
GBD 2017 estimated cause-specific burden for the
years 1990–2017 [4, 12–14]. In this study, we focus on
burden estimates for 2017, with reference to changes
from 1990. All GBD 2017 results for all years and by lo-
cation, including Brazil and its 27 states, can be explored
further in dynamic data visualizations at http://vizhub.
healthdata.org/gbd-compare and http://ghdx.healthdata.
org/gbd-results-tool.
Data sources and processing
The GBD 2017 data sources and analytical process for
general mortality and morbidity estimates and for spe-
cific analysis of TB burden among individuals who were
HIV-positive and HIV-negative have been detailed else-
where [3, 10, 12, 13]. For Brazil, the main mortality data
source used in GBD study was the Brazilian Mortality
Information System (Sistema de Informações sobre
Mortalidade – SIM in Portuguese) database, adjusted by
other national and international sources [18–21]. Vital
registration data were adjusted and corrected for mortal-
ity completeness and redistribution of garbage codes (as-
signment of causes of death that could not or should not
be classified as the underlying cause of death, including
ill-defined codes and the use of intermediate causes) to
more precise underlying causes of death using GBD al-
gorithms and misclassified HIV deaths (i.e., deaths
caused by HIV being assigned to other underlying causes
of death, such as TB or diarrhea, because of stigma or
misdiagnosis) [3, 10, 13]. GBD 2017 used the Cause of
Death Ensemble model (CODEm) strategy to generate
estimates of TB deaths among HIV-negative individuals
by location, age group, sex, and year [3, 10, 13]. The
CODEm approach evaluates a large number of potential
models that apply different functional forms (mixed-ef-
fects models and spatiotemporal Gaussian process re-
gression models) to mortality rates or cause fractions
with varying combinations of predictive covariates and
constructs an ensemble model based on the performance
of the different models [3, 13]. The covariates included
were adult underweight proportion, alcohol (liters per
capita), diabetes (fasting plasma glucose in mmol/L),
education (years per capita), Healthcare Access and
Quality [HAQ] Index, lag-distributed income (LDI), in-
door air pollution, outdoor air pollution, population
density (people per km2), smoking prevalence, cigarettes
per capita, TB strain prevalence-weighted transmission
risk, socio-demographic Index (SDI), prevalence of active
TB, prevalence of latent TB infection, and a summary
exposure variable scalar reflecting the average exposure
to all of the risk factors [13]. The ensemble of CODEm
models that performed best on out-of-sample predictive
validity tests was selected [3, 10, 13]. HIV–TB deaths
were estimated using a population attributable fraction
approach taking into account baseline risk [10, 13]. In
addition, GBD 2017 study addressed and adjusted the
estimates of TB deaths in children for potential mis-
classification of TB deaths as pneumonia deaths in loca-
tions with high TB burden, such as Brazil [13]. A
detailed description of modeling approaches to estimate
TB deaths among HIV-negative and HIV-negative indi-
viduals been reported elsewhere [3, 13].
For estimating non-fatal TB burden, GBD 2017 study
used all available data sources, including annual case no-
tifications, prevalence surveys, population-based tuber-
culin surveys, and estimated cause-specific mortality of
TB among HIV-positive and HIV-negative individuals
[3, 10, 12]. GBD 2017 used DisMod-MR 2.1, a Bayesian
meta-regression tool, to synthesize consistent non-fatal
TB estimates by age, sex, year, and location [3, 10, 12].
This tool adjusts for variations in study methods be-
tween data sources and imposes consistency between
data for different parameters [12]. To distinguish HIV-
TB from all forms of TB, GBD study applied the propor-
tions of HIV-TB cases among all TB cases estimated
from a mixed-effects regression to TB incident and
prevalent cases [10, 12]. The detailed description of the
TB non-fatal modeling and estimation have been re-
ported elsewhere [3, 10, 12]. In Brazil, the main sources
of TB morbidity data used in GBD 2017 were the Notifi-
able Disease Information System (Sistema de Informação
de Agravos de Notificação—SINAN in Portuguese) and
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notification data from the WHO’s global TB database, in
addition to published national and subnational TB
prevalence surveys [12, 18, 20, 21]. The TB morbidity
and mortality data input sources used in GBD 2017 for
Brazil is available at http://ghdx.healthdata.org/gbd-201
7/data-input-sources.
DALY calculation
In this study, DALYs and its components YLLs and
YLDs were used to assess the fatal and non-fatal TB bur-
den in Brazil. Additional details of DALY estimation
methods have been described in the GBD publications
[4]. YLLs were estimated by multiplying the number of
TB deaths in each age by the GBD standard life expect-
ancy at the age of death [4, 13]. In GBD 2017, the stand-
ard life expectancy at birth is 87.9 years, based on the
lowest death rates for each age observed in countries
with a population greater than 5 million [13]. YLDs were
estimated by multiplying the prevalence of each sequelae
or combination of sequelae related to TB by its disability
weights, and then aggregating the estimates for all se-
quelae to the cause level [4, 12]. Disability weights quan-
tify the relative severity of the sequelae on a scale from 0
(perfect health) to 1 (equivalent to death) and were de-
rived from population-based surveys and an open web-
based survey using pairwise comparison methods [4, 12].
Finally, DALYs were computed as the sum of YLLs and
YLDs for each location, age group, sex, and year.
Risk factor estimation
GBD 2017 used comparative risk assessment approaches
to calculate the proportion of DALYs attributable to risk
factors as a counterfactual to the hypothetical situation
that populations had been exposed to a theoretical mini-
mum level of exposure in the past [14]. The inclusion of
a risk–outcome pair was based on the evidence of con-
vincing or probable causal relationship between the risk
and the outcome [14]. For TB among HIV-negative indi-
viduals, estimates were made of three risk factors (high
fasting plasma glucose [HFPG], alcohol use, and smok-
ing) because of evidence of their causal relationship with
the risk of TB [10, 14]. To date, GBD has not quantified
the contribution of some risk factors (e.g., indoor air
pollution and malnutrition) that have been hypothesized
to have a strong link with TB, because of insufficient evi-
dence of a causal relationship [10]. Estimates of attribut-
able DALYs were computed by multiplying DALYs for
the outcome by the population attributable fraction for
the risk-outcome pair for a given age, sex, location, and
year [14].
Results are reported in absolute numbers and age-
standardized rates (per 100,000 inhabitants) of DALYS,
YLLs, and YLDs by sex, age group, year, and location
with their respective 95% uncertainty intervals (UIs)
based on the 25th and 975th values of the ordered 1000
draws of the uncertainty distribution [4, 12, 13].
We report positive and negative percentage changes to
show increasing and decreasing variations between 1990
and 2017, respectively.
Ethical considerations
This study was based on data which are publicly avail-
able and without nominal identification of individual
data. The Project “Global Burden of Diseases—GBD in
Brasil” was approved by the Research Ethics Committee
of the Federal University of Minas Gerais (Universidade
Federal de Minas Gerais—UFMG), Belo Horizonte,
Brazil (protocol number 62803316.7.0000.5149).
Results
Levels and trends of national TB burden
In 2017, the number of DALYs due to TB (HIV-negative
and HIV-positive combined) in Brazil was 284,323 (95%
UI: 240,269–349,265) DALYs in Brazil (Table 1), ac-
counting for 0.5% of national all-cause DALYs (about
60.5 million DALYs). Among HIV-negative individuals,
the number of DALYs was 196,366 (95% UI: 189,645–
202,394) (Additional file 1: Table S1), while 87,957
DALYs (95% UI: 50,624–146,870) were estimated among
HIV-positive individuals (Additional file 2: Table S1).
The number of DALYs due to TB at the national level
decreased by 47.0% as compared to 1990 (535,982
DALYs [95% UI: 469,189–604,253]) (Table 1). The age-
standardized DALY rates declined by 68.5% from 391.68
DALYs/100,000 inhabitants (95% UI: 347.64–436.53) in
1990 to 123.53 DALYs/100,000 inhabitants (95% UI:
104.30–151.83) in 2017 (Table 1). The same pattern of
decline trend between 1990 and 2017 was observed for
the number and age-standardized rates of DALYs due to
TB both among HIV-negative (Additional file 1: Table
S1) and HIV-positive individuals (Additional file 2: Table
S1). YLLs were the main component of total DALYs due
to TB over the period.
Like DALYs, the age-standardized rates of YLLs and
YLDs due to TB at the national level decreased between
1990 and 2017 (Tables 2 and 3; Additional file 1: Tables
S2 and S3; Additional file 2: Tables S2 and S3). However,
higher declines were observed for age-standardized YLL
rates compared to age-standardized YLD rates (Tables 2
and 3; Additional file 1: Tables S2 and S3; Additional file
2: Tables S2 and S3).
TB burden by age and sex
In 2017, the age-standardized DALY rate (HIV-negative
and HIV-positive combined) among males (177.75
DALYs/100,000 inhabitants [95% UI: 151.51–215.89])
was 2.4 times higher than that among females (74.19
DALYs/100,000 inhabitants [95% UI: 60.43–94.67]). The
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number of age-specific DALYs for both sexes combined
was highest in the age groups 30–54 years (with a peak
in the aged 40–44 years) (Fig. 1a). Among HIV-negative
individuals, the number of DALYs was highest among
people aged 50–54 years (Additional file 3: Figure S1-A),
while among HIV-positive individuals, in the aged 30–
35 years (Additional file 4: Figure S2-A).
The age-specific DALY rates for both sexes combined
were highest among children under 1 year (321.98
DALYs/100,000 inhabitants [95% UI: 232.50–443.29])
and in the age groups 45–59 years (> 230 DALYs/100,
000 inhabitants) (Fig. 2a). The similar pattern was ob-
served for both HIV-negative (Additional file 5: Figure
S3-A) and HIV-positive individuals (Additional file 6:
Figure S4-A), with the highest age-specific DALY rates
for both sexes combined observed among children under
1 year. For males, the age-specific DALY rates were
highest in the aged 50–54 years (377.61 DALYs/100,000
Table 3 Number of YLDs and age-standardized YLD rates (per 100,000 inhabitants) from tuberculosis in Brazil and states in 1990
and 2017, with absolute percentage change between 1990 and 2017
Region/State Number of YLDs (95% UI) Age-standardized YLD rates (per 100.000) (95% UI)
1990 2017 % Change
1990–2017
1990 2017 % Change
1990–2017
Brazil 9,030.9 (6,022.1-12,395.5) 10,686.2 (7,002.8-14,963.4) 18.3 6.64 (4.43-9.05) 4.65 (3.05-6.50) -30.0
North
Acre 31.6 (20.6-44.7) 58.1 (37.0-85.0) 83.7 9.54 (6.36-13.25) 6.83 (4.38-9.85) -28.4
Amapá 16.7 (10.9-24.2) 46.6 (29.8-67.0) 179.1 7.74 (5.15-10.90) 5.91 (3.86-8.38) -23.6
Amazonas 168.5 (107.7-238.3) 376.6 (237.6-551.8) 123.4 10.20 (6.71-14.26) 9.60 (6.17-13.88) -5.9
Rondônia 54.9 (34.5-79.1) 65.1 (40.5-96.5) 18.5 5.97 (3.82-8.39) 3.55 (2.23-5.21) -40.5
Roraima 13.0 (8.5-18.8) 27.9 (17.2-40.5) 113.8 7.32 (4.80-10.43) 5.11 (3.21-7.32) -30.1
Pará 303.5 (193.9-437.1) 520.0 (329.5-764.2) 71.3 7.61 (4.97-10.82) 5.92 (3.78-8.70) -22.1
Tocantins 32.5 (20.9-46.9) 52.3 (33.3-75.9) 60.8 4.38 (2.81-6.21) 3.21 (2.03-4.64) -26.8
Northeast
Alagoas 121.7 (79.4-173.9) 148.4 (92.8-219.4) 21.9 5.66 (3.74-8.09) 4.16 (2.61-6.13) -26.5
Bahia 680.5 (441.3-966.4) 798.6 (502.5-1,165.1) 17.4 6.69 (4.40-9.33) 4.87 (3.06-7.10) -27.2
Ceará 346.3 (228.2-495.2) 527.5 (338.0-758.9) 52.4 6.21 (4.09-8.82) 5.19 (3.35-7.44) -16.5
Maranhão 287.1 (184.8-407.3) 383.6 (237.9-559.8) 33.6 7.16 (4.63-10.14) 5.08 (3.20-7.37) -29.1
Paraíba 145.2 (94.2-208.3) 175.7 (111.4-257.3) 21.0 5.16 (3.33-7.40) 3.93 (2.49-5.74) -23.8
Pernambuco 485.5 (316.6-687.5) 636.5 (406.3-926.7) 31.1 7.61 (5.02-10.71) 6.10 (3.91-8.89) -19.8
Piauí 118.7 (77.2-167.9) 164.6 (103.0-237.8) 38.7 5.43 (3.52-7.67) 4.48 (2.80-6.46) -17.4
Rio Grande do Norte 106.8 (69.4-151.5) 167.5 (105.6-248.1) 56.9 4.98 (3.26-7.10) 4.36 (2.75-6.42) -12.5
Sergipe 66.6 (43.3-94.5) 95.4 (60.2-137.2) 43.2 5.20 (3.37-7.30) 3.87 (2.44-5.56) -25.6
Southeast
Espírito Santo 126.0 (80.5-181.8) 149.1 (94.2-213.1) 18.3 5.33 (3.48-7.62) 3.48 (2.21-4.98) -34.8
Minas Gerais 795.3 (505.7-1,138.7) 851.8 (541.2-1,239.0) 7.1 5.43 (3.49-7.64) 3.58 (2.27-5.190 -34.0
Rio de Janeiro 1,076.5 (688.3-1,538.1) 1,353.5 (864.3-1,991.1) 25.7 8.21 (5.31-11.65) 6.88 (4.40-10.11) -16.1
São Paulo 2,319.8 (1,434.3-3,299.3) 2,142.1 (1,374.5-3,108.4) -7.7 7.38 (4.69-10.39) 4.24 (2.72-6.14) -42.6
South
Paraná 417.9 (265.7-604.1) 385.6 (240.0-553.7) -7.7 5.34 (3.45-7.66) 3.09 (1.94-4.42) -42.1
Rio Grande do Sul 673.6 (436.2-958.3) 690.7 (441.8-1,008.3) 2.5 7.43 (4.93-10.59) 5.40 (3.44-7.94) -27.4
Santa Catarina 199.9 (126.7-287.3) 247.3 (155.1-364.0) 23.7 4.70 (3.02-6.70) 3.17 (1.99-4.68) -32.6
Central-West
Distrito Federal 66.1 (43.0-95.4) 95.3 (59.3-141.2) 44.3 4.55 (3.05-6.48) 3.00 (1.88-4.39) -34.1
Goiás 146.2 (94.0-210.3) 194.1 (121.8-284.4) 32.7 3.99 (2.61-5.70) 2.63 (1.67-3.84) -33.9
Mato Grosso 123.1 (79.3-174.6) 192.7 (119.9-285.1) 56.6 7.20 (4.64-10.09) 5.17 (3.26-7.61) -28.2
Mato Grosso do Sul 107.2 (67.0-151.6) 139.4 (88.4-203.3) 30.0 6.73 (4.34-9.34) 4.67 (2.99-6.79) -30.6
YLDs years lived with disability, 95% UI 95% uncertainty interval
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Fig. 1 Absolute number of age- and sex-specific a DALYs, b YLLs, and c YLDs from tuberculosis in Brazil, 2017. DALYs disability-adjusted life-years,
YLLs years of life lost, YLDs years lived with disability
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Fig. 2 Age- and sex-specific rates (per 100,000 inhabitants) of a DALYs, b YLLs, and c YLDs from tuberculosis in Brazil, 2017. DALYs disability-
adjusted life-years, YLLs years of life lost, YLDs years lived with disability
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inhabitants [95% UI: 321.16–456.12]), while for females
were observed in children under 1 year (272.27 DALYs/
100,000 inhabitants [95% UI: 195.50–375.27]) (Fig. 2a).
Among HIV-positive individuals, the DALY rates for
males were highest in children under 1 year (Additional
file 6: Figure S4-A).
Similar to DALYs, the age-specific rates of YLLs and
YLDs due to TB were highest in males. The age-specific
YLL rates for both sexes combined were highest among
children under 1 year (321.29 YLLs/100,000 inhabitants
[95% UI: 231.76–442.44) (Fig. 2a). Among HIV-negative
individuals, the highest age-specific YLL rates for both
sexes combined were observed among children under 1
year and in the aged 55–59 years (Additional file 5: Fig-
ure S3-B), while among HIV-positive individuals, the
highest YLL rate was observed among children under 1
year (Additional file 6: Figure S4-B). For males, the age-
specific YLL rates were highest among children under 1
year and in the age groups 45–59 years (> 360 YLLs/100,
000 inhabitants), while for females were observed in
children under 1 year (271.65 YLLs/100,000 inhabitants
[95% UI: 194.60–374.58]) (Fig. 2b).
The age-specific YLD rates due to TB for both sexes
combined were highest among those aged above 85
years, with a peak in the age group 95 years and older
(8.13 YLDs/100,000 inhabitants [95% UI: 5.10–12.14])
(Fig. 2c). Among HIV-positive individuals, the age-
specific YLD rates for both sexes combined were highest
in the age group 35–39 years (Additional file 6: Figure
S4-C). For males, the highest age-specific YLD rate was
observed in the age group 95 years and older (14.47
YLDs/100,000 inhabitants [95% UI: 8.98–21.70]), while
for females was observed in the age group 65–74 years
(> 5.25 YLDs/100,000 inhabitants) (Fig. 2c).
Regional variations in TB burden
Table 1 presents the number of DALYs and age-
standardized DALY rates due to TB (HIV-negative and
HIV-positive individuals combined) by Brazilian states
for 1990 and 2017. Estimates of DALYs due to TB
among HIV-negative and HIV-positive individuals by
Brazilian states are presented in Additional file 1: Table
S1 and Additional file 2: Table S1, respectively. In 2017,
the number of DALYs due to TB was highest in the
states of São Paulo, Rio de Janeiro, and Bahia, whereas
the age-standardized DALY rates (> 220 DALYs/100,000
inhabitants) were highest in the states of Rio de Janeiro,
Pernambuco, and Amazonas (Fig. 3). A similar pattern
was also observed for both HIV-negative (Additional file
7: Figure S5) and HIV-positive individuals (Additional
file 8: Figure S6), with the highest age-standardized
DALY rates observed in the same Brazilian states. The
age-standardized DALY rates due to TB decreased for
all 27 Brazilian states between 1990 and 2017, with the
highest decreases observed in the states of São Paulo,
Distrito Federal, Maranhão, Rondônia, and Alagoas (a
relative reduction of 70% or more), while the smallest
decreases were observed in the states of Amapá, Rio
Grande do Sul, Amazonas, and Mato Grosso do Sul
(Table 1).
The age-standardized YLL rates were highest in the
states of Rio de Janeiro, Pernambuco, and Amazonas,
with a declining trend of age-standardized YLL rates for
all Brazilian states between 1990 and 2017 (Table 2).
The age-standardized YLD rates were highest in the
states of Amazonas, Rio de Janeiro, and Acre (Table 3).
Age-standardized YLD rates decreased for all 27 Brazil-
ian states between 1990 and 2017, with slower declines
in age-standardized rates when compared to YLLs
(Table 3). Among HIV-positive individuals, the age-
standardized YLD rates were highest in the states of
Amazonas, Rio de Janeiro, and Rio Grande do Sul, with
an increasing trend of age-standardized YLD rates in
several Brazilian states between 1990 and 2017 (Add-
itional file 2: Table S3).
TB burden attributable to risk factors
In 2017, 59.0% (115,819 DALYs [95% UI: 97,688–131,
549]) of total DALYs due to TB among HIV-negative in-
dividuals in Brazil were attributable to alcohol use,
smoking, and diabetes, compared to 43.6% (173,820
DALYs [95% UI: 151,254–194,654]) of total DALYs in
1990. Alcohol use accounted for 47.5% of national
DALYs due to TB in 2017, smoking for 17.9%, and dia-
betes for 7.7% (Fig. 4). The proportion of DALYs due to
TB attributable to three risk factors decreased between
1990 and 2017, with a higher decline of DALYs attribut-
able to smoking (percentage change: − 61.4%) than com-
pared with those attributable to diabetes (− 27.4%) and
alcohol use (− 19.6%).
Discussion
This study is the first comprehensive national assess-
ment of the levels and trends in fatal and non-fatal bur-
den of TB in Brazil over 28 years (1990–2017). GBD
2017 findings showed a consistent decreasing trend of
age-standardized DALY rates at the national level and
all Brazilian states from 1990 to 2017, driven primarily
by a faster decrease in the age-standardized YLL rates,
the main component of total DALYs due to TB. The
highest TB burden was observed among males, middle-
aged adults and children under 1 year, and in highly en-
demic states for the disease in Brazil. HIV-TB comprised
about 31% of DALYs due to TB and alcohol use was the
leading risk factor for the attributable TB burden among
HIV-negative individuals in 2017.
The high TB burden in males observed in the GBD
2017 study reflects the patterns of the disease in Brazil
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since most of the TB cases and deaths are recorded in
this gender in the country [6, 22]. The predominance of
fatal and non-fatal burden due to TB among males can
be explained by the higher exposure to bacillus in work
activities and the frequency of risk behaviors for the
disease in this gender, such as higher consumption of al-
coholic beverages, smoking, and drug use [10, 23]. Be-
sides, the highlights was sex difference in TB risk due to
health care behavior, such as lower self-care, lower de-
mand for health care, and lower adherence and greater
abandonment loss of follow-up to TB treatment among
males [10, 24, 25]. Thus, an understanding of the sex
distribution of TB cases and deaths has implications for
TB control programmes concerning targeting of inter-
ventions to high-risk groups [10].
The highest number of DALYs and age-specific DALY
rates for TB observed among middle-aged adults (35–64
years) corroborates with age-specific patterns of disease in
the country [22]. The highest concentration of TB burden
in the age group of greater economic productivity
Fig. 3 Age-standardized DALY rates (per 100,000 inhabitants) from tuberculosis by states in Brazil for 1990 and 2017. DALY disability-adjusted life-years
Fig. 4 Number of tuberculosis DALYs (with 95% uncertainty intervals) attributable to alcohol use, smoking, and diabetes in Brazil, 2017. DALYs
disability-adjusted life-years
Martins-Melo et al. Population Health Metrics 2020, 18(Suppl 1):10 Page 12 of 17
generates a socio-economic impact on patients, their fam-
ily, and society, causing more poverty and social exclusion
[8]. Also, it is important to highlight the high DALY rate
due to TB in children under 1 year of age, primarily due
to the high rates of fatal burden estimated in this age
group [13]. The high burden of premature TB deaths in
this age group observed in GBD 2017, different of the pre-
vious GBD cycles, might be explained by the changes in
the estimation process with adjustments and corrections
for potential misclassification of TB deaths in children [3,
13]. In locations with high TB burden, such as Brazil, TB
mortality in children may be underestimated because
many children deaths caused by TB may be erroneously
attributed to more common diseases in this age, such as
pneumonia, HIV/AIDS, and meningitis [26–29]. GBD
2017 estimates identify a prime opportunity to address an
under-recognized and preventable cause of premature
death in children under 1 year, and should motivate the
ongoing development of better methods for detecting or
preventing cases of pediatric TB [3]. Although TB is cur-
able, diagnostic methods for TB have poor performance
due to difficulties obtaining samples and paucibacillary
form in children [28]. Thus, the dramatic reduction of
pediatric TB burden requires better diagnostic technology,
along with significant advances in treatment and vaccin-
ation [29]. However, in the meantime, more consistent
preventive treatment for children exposed to TB and more
persistent assessment of potential pediatric TB cases can
take too long before leading to a reduction in the mortal-
ity burden [29]. Efforts for the prevention, diagnosis, and
treatment of childhood TB should consider the peculiar-
ities of the disease in this age group, ensuring the early
identification and treatment of active and latent TB infec-
tion (LTBI) and using more sensitive and less invasive
methods for the diagnosis of extrapulmonary and pauciba-
cillary pulmonary TB [30].
We observed regional variations in the TB burden
among Brazilian states. Except for the state of Rio de
Janeiro (Southeast region), the highest age-standardized
DALY rates in 2017 were observed in states of the North
and Northeast regions. The findings of TB burden by
Brazilian states corroborate with the observed patterns
of regional TB morbidity and mortality in the country
[22, 31]. The highest mortality and incidence rates of TB
were observed in the states of Rio de Janeiro, Pernam-
buco, and Amazonas [6, 22]. This pattern of TB distribu-
tion can be explained in part by the occurrence of cases
and deaths that are concentrated mainly in peripheral
urban areas, with clusters of patients living in extreme
poverty and inadequate housing, facilitating the trans-
mission of the disease, a scenario mainly observed in the
states of Rio de Janeiro and Pernambuco [6, 32, 33]. In
the states of North region, in addition to the close rela-
tionship of TB burden with precarious living conditions
and densely populated areas in some cities in this region,
stands out the occurrence of TB in indigenous popula-
tion, a recognized vulnerable group for TB and other
major endemic diseases in the Amazon region, which
may influence in part the TB burden in some areas with
a high proportion of this population in the region [34].
The steady decline of age-standardized DALY rates
due to TB at the national level from 1990 to 2017
corroborates the observed patterns of decreasing
trends in TB mortality and incidence in the last de-
cades [6, 22]. Substantial progress has been made in
reducing TB incidence and mortality in Brazil, with
the country meeting the Millennium Development
Goals (MDGs) targets for TB control by 2015 [31, 35,
36]. This reduction can be explained by the progress
in the access and quality of diagnostic and treatment
services provided to patients with TB combined with
improvements in the living conditions of the Brazilian
population [37]. However, despite the general progress
in the reduction of TB mortality and morbidity, the
disease burden and its control still remain a challenge
[6, 31]. The progress is not homogeneous among
states and municipalities, and is insufficient to reach
the agreed global targets for End TB Strategy [37]. In
this sense, compliance with the goals established by
WHO and SDGs and agreed by the Brazilian Ministry
of Health will be difficult to achieve without major
and profound changes in the access, coverage, and
quality of the health care provided, adherence to a so-
cial protection agenda, and changes in the regional
economic and political context [30, 36]. Thus, efforts
should be made to strengthen TB surveillance and
control actions in Brazil through systematic strategies
that promote and improve access to prevention, early
diagnosis and timely treatment, and appropriate
follow-up of TB cases, seeking to reduce TB cases
and deaths in the country [1, 38]. Along with intensi-
fying the active search for TB cases, further efforts
should be made to prioritize the systematic screening
and control of household contacts of bacteriologically
confirmed pulmonary TB cases, which allows the
identification of people with LTBI, enabling receiving
TB preventive treatment to reduce the risk of pro-
gression to active TB, in addition to diagnose early
cases of active disease and start treatment timely [1,
38]. Since TB is an infectious disease that is strongly
related to social inequality in Brazil, this reinforces
the need to intensify multisectoral actions addressing
the economic and social determinants of TB infection
and disease, giving special attention to poor and vul-
nerable populations and communities especially at
risk [1, 39]. The implementation and expansion of
public initiatives for social protection and poverty al-
leviation, such as the Bolsa Família Programme, the
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national conditional cash transfer programme, can
contribute in TB prevention and care and to favorable
TB treatment outcomes among vulnerable populations
in Brazil [39, 40].
The considerable proportion of estimates of DALYs due
to TB among HIV-positive individuals reinforces the epi-
demiological relevance of TB-HIV co-infection as a co-
morbidity of significant impact on public health in Brazil
[41, 42]. Currently, despite the improvements in the qual-
ity of management and care of TB in people living with
HIV/AIDS and increased access to active antiretroviral
therapy (ART) in Brazil, morbidity and mortality due to
TB continues remains high among HIV-positive people in
the country, impacting negatively the survival and quality
of life of this population [43]. TB is the leading cause of
death among infectious diseases defined in HIV/AIDS pa-
tients in the country [44, 45]. The two diseases (mainly
TB) are mostly concentrated in areas of poverty where
there are minimal resources for the diagnosis, treatment,
and control of infection, and public health services do not
meet the needs for control of both pathologies [41, 46].
The Brazilian Ministry of Health recommends that all pa-
tients with TB undergo HIV serological testing [45]. This
procedure allows an early diagnosis of HIV infection,
allowing, when indicated, the timely initiation of ART,
which has a significant impact on the survival of these pa-
tients and resulting in a reduction in its morbidity and
mortality [10, 45]. Despite this orientation, low rates of
HIV screening in some Brazilian areas with poorer health
service structure is observed, which increases the uncer-
tainty about the real magnitude of TB-HIV co-infection
and makes difficult its early diagnosis and timely ART ini-
tiation [41, 45, 47]. Furthermore, it is important to high-
light the influence of social stigma and prejudice
regarding the two diseases as negative implication in the
timely diagnosis and adequate treatment of TB-HIV cases
[48]. In this context, in order to overcome the challenges
of reducing the burden of co-infection in the country, re-
inforces the need for greater integration between TB and
HIV control programs and services, with a multidisciplin-
ary approach and integral care, regarding the early identi-
fication of co-infection and timely use of ART and the TB
treatment regimen, considering that these actions are
mainly aimed in improving the quality of life and reducing
the severe TB-HIV cases and deaths [10, 49].
The assessment of the contribution of potentially
modifiable risk factors is also a crucial input into TB
control policy [10]. Nationally, GBD 2017 estimated that
alcohol use, smoking, and diabetes together accounted
for about 60% of the proportion of DALYs due to TB
among HIV-negative people in 2017. These risk factors
could increase the risk of TB through suppression of the
immune system, especially cell-mediated immunity [50–
53]. Alcohol use, the leading risk factor observed in the
study, causes a decline in immunity, malnutrition, and
social fragility, being considered as an important risk
factor for the development of TB, but it also influences
the outcome of TB treatment and prognosis [10, 51, 53,
54]. Therefore, efforts to prevent these health-related
risk factors, along with HIV, can have a substantial im-
pact on the TB burden [3, 10].
The general limitations of the GBD 2017 approach
and those for estimation of TB burden are described
elsewhere [3, 4, 12–14, 16]. GBD specific limitations for
Brazil, such as coverage, quality, and availability of epi-
demiological data used to estimate the disease burden,
have also been detailed in previous publications [18, 19,
55]. For mortality data, although the SIM database has
experienced substantial improvements and progress in
coverage and quality of information on causes of death
since 1990, mortality coverage and proportion of ill-
defined causes presented variations among the Brazilian
states, with higher proportion of underreporting of
deaths and ill-defined causes of death in some states in
the North and Northeast regions [18, 55, 56]. Further-
more, the underlying cause of death may have been
coded as a complication or aggravation associated with
TB [57]. Although the GBD study uses comparable and
standardized methods processes for correction of under-
reporting of deaths and redistribution of garbage codes,
the regional variations can substantially affect mortality
estimates, which should be interpreted with caution for
some Brazilian states [13, 19, 21].
For non-fatal data, despite improvements in the cover-
age and quality of epidemiological surveillance data for
TB in the country (SINAN database) in recent years, spe-
cific limitations such as the underreporting or incorrect
reporting of TB cases and completeness of the variables
can occur in locations with precarious structure of
health services [56, 58]. This can present critical chal-
lenges to the production of accurate estimates of non-
fatal TB burden, particularly at the state level [3, 10].
Thus, the TB estimates for some Brazilian locations with
limited high-quality data are reflected in the wide uncer-
tainty intervals [3, 10].
Despite these limitations, the levels and trends of TB
burden are consistent with the epidemiological patterns
of the disease in the country. In addition, the GBD esti-
mates are relevant to demonstrate the importance of TB
as a cause of years of healthy life lost due to premature
death and disability in Brazil and its states, besides to
provide an up-to-date comparative assessment of TB
burden with other countries or regions.
Conclusions
GBD 2017 results show that, despite general progress in
reduction of TB burden in Brazil during the 28-year
study period (1990–2017), the disease is still an
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important preventable and treatable cause of health loss
due to premature death and disability. The TB burden
was higher in males, children under 1 year and middle-
aged adults (aged 40–64 years), and in the Brazilian
states with the highest incidence/mortality rates. The
findings reinforce the importance of strengthening con-
trol and surveillance strategies in Brazil through inte-
grated and multisectoral actions that enable the access
to prevention, early diagnosis, and timely and adequate
treatment of TB, with emphasis on high-risk groups and
populations most vulnerable to the disease.
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